Literature DB >> 1912953

Role of splenectomy in incidence and severity of acute graft-versus-host disease: a multicenter study of 157 patients.

M Michallet1, B Corront, J L Bosson, L Molina, B Peissel, D Maraninchi, J Reiffers, C Chabannon, M H Gaspard, A M Stoppa.   

Abstract

Allogeneic bone marrow transplantation is a therapeutic option for many hematological malignancies. Graft-versus-host disease (GVHD) remains one of the major complications and has a high mortality rate. The pathophysiological mechanisms involved are poorly understood and GVHD prevention regimens still give disappointing results. This study concerned 157 patients with diverse diagnoses from Bordeaux, Grenoble and Marseille who had undergone an HLA-matched transplantation without T cell depletion. Thirty-one patients (20%) had been splenectomized before transplantation. The role of splenectomy in the incidence and severity of acute GVHD was investigated using a univariate and multivariate analysis of 11 risk factors including splenectomy. Univariate analysis found three significant risk factors linked with GVHD incidence: splenectomy, age of recipient and GVHD prevention by monotherapy versus a combination of methotrexate plus cyclosporin. Multivariate analysis retained only the effects of age and GVHD prevention on GVHD incidence and showed that splenectomy was the most important factor in GVHD severity. One explanation for the role of splenectomy could be the spleen's possible function as a filter of activated T lymphocytes from the transplant. We therefore concluded that it would be preferable to abstain from splenectomizing patients before transplantation although splenectomy is still advisable in certain malignancies after transplantation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1912953

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

1.  Splenectomy prior to allogeneic hematopoietic SCT increases the risk of post-transplant lymphoproliferative disease.

Authors:  M Uhlin; M M Norström; J Mattsson; M Remberger
Journal:  Bone Marrow Transplant       Date:  2013-12-16       Impact factor: 5.483

Review 2.  Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Authors:  Rachel B Salit; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2014-10-03       Impact factor: 3.722

3.  Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.

Authors:  Theresa Hahn; Philip L McCarthy; Mei-Jie Zhang; Dan Wang; Mukta Arora; Haydar Frangoul; Robert Peter Gale; Gregory A Hale; John Horan; Luis Isola; Richard T Maziarz; Jon J van Rood; Vikas Gupta; Joerg Halter; Vijay Reddy; Pierre Tiberghien; Mark Litzow; Claudio Anasetti; Stephen Pavletic; Olle Ringdén
Journal:  J Clin Oncol       Date:  2008-11-03       Impact factor: 44.544

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.